Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
Li Wang; Markus H Kainulainen; Nannan Jiang; Han Di; Gaston Bonenfant; Lisa Mills; Michael Currier; Punya Shrivastava-Ranjan; Brenda M Calderon; Mili Sheth; Brian R Mann; Jaber Hossain; Xudong Lin; Sandra Lester; Elizabeth Pusch; Joyce Jones; Dan Cui; Payel Chatterjee; Harley M Jenks; Esther Morantz; Gloria Larson; Masato Hatta; Jennifer Harcourt; Azaibi Tamin; Yan Lin; Ying Tao; Kun Zhao; Kristine Lacek; Ashely Burroughs; Terianne Wong; Suxiang Tong; John R Barnes; Mark W Tenforde; Wesley H Self; Nathan I Shapiro; Matthew C Exline; D. Clark Files; Kevin W Gibbs; David N Hager; Manish Patel; Alison S Laufer Halpin; Laura K McMullan; Justin S Lee; Hongjie Xia; Xuping Xie; Pei-Yong Shi; C. Todd Davis; Christina F Spiropoulou; Natalie J. Thornburg; M. Steven Oberste; Vivien Dugan; - SSEV Bioinformatics Working Group; David E Wentworth; Bin Zhou.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-469906
IntroductoryThe evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of many new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccines. To ascertain and rank the risk of VOCs and VOIs, we analyzed their ability to escape from vaccine-induced antibodies. The variants showed differential reductions in neutralization and replication titers by post-vaccination sera. Although the Omicron variant showed the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retained moderate neutralizing activity against that variant. Therefore, vaccination remains the most effective strategy to combat the COVID-19 pandemic.
Texto completo
Documentos relacionados